Editorial Open Access
Volume 6 | Issue 1 | DOI: https://doi.org/10.46439/toxicology.6.028
Non-alcoholic fatty liver disease (NAFLD): The burgeoning liver disease at the interface of metabolic syndrome and type 2 diabetes
Shakil A Saghir, M.Sc., M.S.P.H., Ph.D., DABT, ERT, Fellow ATS, Fellow RSB1,2,3, Dileep K Rohra4, Riyadh S. Almalki5, Rais Ansari, Ph.D.6,*
- 1President, ToxInternational Inc., Hilliard, OH, USA
- 2Visiting Professor, Department of Biological & Biomedical Sciences, Aga Khan Univ, Karachi, Pakistan
- 3Professor, Institute of Environmental Science and Meteorology, University of the Philippines-Diliman, Quezon City, Philippines
- 4Professor and Chair, Department of Pharmacology, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
- 5Assistant professor, Department of Pharmacology and Toxicology, Faculty of Pharmacy, Umm AL-Qura University, Makkah 21421, Saudi Arabia
- 6Associate Professor, Department of Pharmaceutical Sciences, Barry and Judy Silverman College of Pharmacy, Health Professions Division, Fort Lauderdale, FL, USA
Corresponding Author
Rais Ansari, ra557@nova.edu
Received Date: March 25, 2024
Accepted Date: April 02, 2024
Saghir SA, Rohra DK, Almalki RS, Ansari R. Non-alcoholic fatty liver disease (NAFLD): The burgeoning liver disease at the interface of metabolic syndrome and type 2 diabetes. Arch Clin Toxicol. 2024;6(1):19-20.
Copyright: © 2024 Saghir SA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Drug delivery via the upper nasal space: A novel route for anesthesiologists, intensivists and emergency department physicians?
Many drugs are effective systemically, but slow onset of non-intravenous routes of administration may limit their clinical utility. While anesthesiologists usually have intravenous (IV) access for drug delivery, other healthcare professionals in less controlled situations such as acute crises in the emergency room, critical care settings, or urgent needs in the community, may need non-invasive drug delivery [1].
Commentary on “Discussing diabetes, palliative care and end of life care: choosing the right language”
Our paper entitled “Discussing diabetes, palliative care and end of life care: choosing the right language” reports a core aspect of our research program, which focuses on older people with diabetes, palliative and end of life care for people with diabetes, and the effect of language on clear communication, that commenced in 2009 [1].
Current understanding of gender dimorphism regarding type 2 diabetes
Today, both type 1 and type 2 diabetes mellitus affect 33.3 million people in the United States and nearly 500 million adults worldwide, and there is concern that this number may increase steadily in the future. Previous studies have linked the development of type 2 diabetes to multiple lifestyle factors, including physical activity level and diet, and biological characteristics, such as body composition, age, and race; however, current research suggests that gender may also have an impact on one’s risk of developing type 2 diabetes. Variations in type 2 diabetes diagnosis, prevalence, and progression have been found between males and females.
Potential enhanced association between obstructive lung disease and history of depression in patients with diabetes
Depression is one of the most common comorbidities of chronic diseases including diabetes and obstructive lung diseases (emphysema, chronic bronchitis, and asthma). Obstructive lung diseases and depression have few symptoms in common. However, they are both common in adults and associated with chronic inflammation. It is not clear if their coappearance in diabetic patients is coincidental or associated beyond that expected by chance.
Molecular signatures of aggressive pediatric liver cancer
Liver masses account for 5 to 6% of pediatric cancer, which includes hepatoblastoma (HBL) along with rare cases of hepatocellular carcinoma (HCC). The most dangerous form of pediatric liver cancer is aggressive HBL, which can be characterized by chemo-resistance and multiple nodules or metastases at diagnosis, all correlating with worse clinical prognosis. Despite intensive studies and a significant improvement in overall outcomes, very little is known about the key molecular pathways which determine the aggressiveness of pediatric liver cancer.